BriaCell Therapeutics Corp. $BCTX

What the company doesAI summary of filing

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The company's lead candidate, Bria-IMT, is a whole-cell immunotherapy currently in a pivotal Phase 3 study for metastatic breast cancer in combination with an immune checkpoint inhibitor and has received FDA Fast Track Designation. The company also is developing Bria-OTS, a personalized off-the-shelf immunotherapy platform, and next-generation candidates including Bria-PROS+ for prostate cancer and Bria-BRES+ for breast cancer, along with antibody therapeutics through its subsidiary BriaPro. BriaCell is pre-revenue and relies on third-party contract manufacturers for production. [10-K 2025-10-16]

Segments: Bria-IMT (metastatic breast cancer immunotherapy), Bria-OTS/Bria-BRES (personalized off-the-shelf breast cancer immunotherapy), Bria-PROS+ (prostate cancer immunotherapy), BriaPro antibody therapeutics (B7-H3 and TILsRx platform)